Marina will receive royalties from the sale of CRN-based reagents. Moreover, this Agreement will establish a ready supply of CRN amidites for Marina’s therapeutic research and development effots.
In August, NYBC announced a partnership with the University of California, Davis, Health System to manufacture specialized lines of stem cells as potential therapies for the repair and
Each year, there are approximately 1,500 new cases of MCC diagnosed in the US. Avelumab (also referred to as MSB0010718C) is an investigational fully human monoclonal IgG1 antibody
Opdivo is the first anti PD-1 (programmed death-1) approved to treat previously untreated cases of BRAF V600 wild-type unresectable or metastatic melanoma in adults. The approval was made
The study, RADIANT-4, will be presented at the European Cancer Congress (ECC) 2015 in Vienna, Austria, and was highlighted in the ECC press conference on Saturday, September 26.
According to the Centers for Disease Control and Prevention, approximately 21 million people in the United States have been diagnosed with diabetes. Over time, diabetes increases the risk
As part of the agreement, MedImmune has in-licensed from 3M MEDI9197 (formerly 3M-052), a novel TLR 7/8 dual agonist. The US Food and Drug Administration recently accepted an
Tamibarotene is a first-in-class selective agonist to retinoic acid receptor alpha (RARa), a nuclear hormone receptor which regulates transcription. Using Syros’ proprietary gene control discovery and development platform,
MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1), an immunomodulatory enzyme, is required for the effective triggering of an immune response. However, dysregulation of MALT1 is also associated
Atlas joins previous seed investors Forbion Capital Partners (Forbion) and Omega Funds (Omega) as investors in this funding round. Replimune, headquartered in Oxford UK and with a significant
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.